A J&J toxicologist testified he found no evidence the company shared an asbestos-in-talc report with the FDA, a development that could reshape mass-tort settlement strategy.
A former Johnson & Johnson toxicologist testified by video deposition that he could find no evidence the company transmitted to the FDA a report that "unmistakably" identified asbestos in its talc products [1]. The jury in the second California bellwether talc trial heard the deposition as plaintiffs pressed their theory that J&J concealed material safety findings from federal regulators [1]. The testimony placed internal scientific conclusions directly at the center of the company's disclosure record with the agency.
The trial is proceeding in Los Angeles Superior Court as part of coordinated talc-ovarian cancer proceedings, one of three pairs of bellwether cases selected to test jury response in California state court [2]. It follows the first California bellwether, which returned a $40 million verdict against J&J in December 2025 [2]. The coordinated proceedings advanced after a federal bankruptcy court rejected J&J's third attempt to resolve its talc liability through a subsidiary Chapter 11 filing in March 2025, leaving thousands of state and federal claims to proceed through conventional litigation [2].
The deposition testimony carries weight beyond this single trial. J&J faces more than 58,000 pending talc-related cases in federal multidistrict litigation, and California's coordinated docket adds additional exposure [1] [2]. Evidence that a company toxicologist, retained in the 1970s, produced findings of asbestos contamination and that those findings may never have reached the FDA gives plaintiffs a concrete regulatory-concealment narrative to carry into settlement negotiations and future trials [1]. Juries presented with internal documents showing a gap between what scientists found and what regulators received have historically responded to that gap as evidence of corporate bad faith, which in mass tort litigation affects both compensatory and punitive damages calculations.
The selection of bellwether cases is designed to produce data points that inform global settlement discussions. A second plaintiff verdict in California, particularly one shaped by regulatory-concealment evidence, would increase pressure on J&J to revise the valuation assumptions underlying any future resolution proposal. The company has not announced a fourth bankruptcy or structured settlement attempt since March 2025 [2]. Trial observers expect the remaining bellwether pairs in the California proceedings to conclude before the end of 2026, giving both sides a fuller damages range before any renewed global negotiations.